EuroBiotech: More Articles of Note


> Argenx pulled off an $100 million (€90 million) Nasdaq IPO. The fundraising haul came in above argenx’s initial target, largely because it offered more shares than originally planned. Argenx will use the cash to take its autoimmune candidate ARGX-113 to the start of a phase 3 trial. Release

> Verona Pharma sold off part of the over-allotment offered in its Nasdaq IPO. The sale of the stock added $9.3 million to Verona’s gross fundraising total. Verona went public in the U.S. to fund midphase trials in chronic obstructive pulmonary disease and cystic fibrosis. Statement

> Alcobra parted company with its CEO. Yaron Daniely, Ph.D. is stepping down at the end of the month to take the top job at tech transfer company Yissum, ending his seven-year stint as CEO of Alcobra. Chief commercial officer David Baker is taking over as CEO on an interim basis. Release

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

> Cinfa Biotech posted top-line data from a clinical trial of its biosimilar copy of Amgen’s Neulasta. The Spanish biotech said the pharmacodynamics and immunogenicity of its copycat matched up to Neulasta, teeing it up to file for approval in Europe in the second half of the year. Statement

> AptaTargets raised €2.7 million to move its treatment for acute ischemic stroke into a phase 1/2 trial. Caixa Capital Risc and Inveready put up the money. AptaTargets will use the money to wrap up preclinical development of its aptamer candidate. Release

> Shares in Nanobiotix climbed following the publication of data on NBTXR3. The data linked the NBTXR3 to an uptick in immune cell infiltration, boosting expectations that the radio enhancer can make “cold” tumors “hot.” Statement